TBIO

Translate Bio Inc.

A maker of messenger RNA (mRNA) medicines, Translate Bio developed therapies that use mRNA to instruct the body's cells to produce proteins that treat disease, including a candidate for cystic fibrosis. It began in 2011 as RaNA Therapeutics, built on research from a Massachusetts General Hospital lab, and renamed itself Translate Bio in 2017 after buying Shire's mRNA therapy platform. The French drugmaker Sanofi acquired the company in 2021.

No Schedule 13D or 13G filings recorded.